Home

PAUL THOMAS

CIK 1166776 · President and CEO · last filed 2026-06-26

PAUL THOMAS is a President and CEO who has filed 75 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for AXGN, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$15.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions. 26 SEC filings were submitted jointly with ABIOMED INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.39M

Companies

11

Total Filings

75

Lifetime Open-Market Net

-$15.32M

Filer Profile

Reported Address
ONE MILLENNIUM WAY
BRANCHBURG, NJ 08876
Related Filers
ABIOMED INC — 26 joint filings, latest 2022-12-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AXGN Director 32,395 $42.16 $1.37M -$633.7K 12 2026-06-26
TELA Director 23,600 $0.97 $22.9K $0 1 2026-06-11
ABIOMED INC (ABMD) Delisted Director 6,357 $381.02 $2.42M -$3.42M 13 2022-11-03
SURGALIGN HOLDINGS, INC. (SRGA) Delisted Director 28,610 $0.18 $5.2K $0 3 2022-08-17
RTI SURGICAL, INC. (RTIX) Delisted Director 0 — — $0 5 2019-03-11
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted Director 0 — — $0 6 2016-11-30
Roka BioScience, Inc. (ROKA) Delisted President and CEO 85,494 — — $0 4 2016-11-10
ABIOMED INC (APOL) Delisted Director 22,932 — — -$2.60M 11 2016-08-11
KINETIC CONCEPTS INC (KCI) Delisted President, LifeCell Corp. 0 — — $0 1 2008-08-27
LIFECELL CORP (VITA) Delisted Chairman, President and CEO 0 — — -$8.66M 10 2008-06-04
AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted Director 38,931 — — $0 1 2007-03-05

Recent Filings

75 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 AXGN Grant (A) — $0 EDGAR
2026-06-23 AXGN Exer (M) +18,867 $0 EDGAR
2026-06-11 TELA Grant (A) +23,600 $0 EDGAR
2025-12-10 AXGN Sell (S) −21,399 -$633.7K EDGAR
2025-12-09 AXGN Notice (144) −21,399 -$633.7K EDGAR
2025-06-20 AXGN Grant (A) — $0 EDGAR
2024-09-17 AXGN Grant (A) +2,875 $0 EDGAR
2024-09-04 AXGN Exer (M) +11,904 $0 EDGAR
2024-06-10 AXGN Grant (A) +10,653 $0 EDGAR
2023-09-07 AXGN Grant (A) — $0 EDGAR
Showing 1–10 of 75
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.